Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 27, 2026Current Medical Research and Opinion

A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNaresh BummaHLHans C. LeeJRJoshua Richter

Discussion

Loading...

Member takes

Overview

Systematic review assesses efficacy of CAR-T and bsAb therapies for triple-class exposed relapsed/refractory multiple myeloma, suggesting new treatment options.

Key Points

  • This review evaluates the efficacy of chimeric antigen receptor T-cell and bispecific antibody therapies for relapsed/refractory multiple myeloma.
  • Systematic search for indirect treatment comparisons of CAR-T and bsAb therapies targeting BCMA and GPRC5D.
  • Used language models and researchers for screening, with full-text review conducted by two researchers.
  • Qualitative synthesis of results from included matching-adjusted indirect comparisons.
  • Elranatamab demonstrated significant improvements versus teclistamab for overall response rate, duration of response, progression-free survival, and overall survival.
  • Linvoseltamab showed notable efficacy improvements against multiple comparators, including elranatamab and talquetamab across various endpoints.
  • Cilta-cel exhibited significant advantages over linvoseltamab and ide-cel for several efficacy outcomes, including overall response rate and overall survival.

Cite This Study

Bumma et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6922aea7db3c1953ff6chttps://doi.org/10.1080/03007995.2026.2686032
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).2024 · 6 citations
  2. 2LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma2022 · 251 citations
  3. 3A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma2024 · 20 citations
  4. 4The PRISMA 2020 statement: an updated guideline for reporting systematic reviews2021 · 105,555 citations
  5. 5Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma2025 · 9 citations